Izindaba
-
Umbiko Omusha Womthetho
1. Imithetho Emisha Yokubhaliswa Kwe-FDA Yezimonyo Zezimonyo Zase-US Ngaphandle Kokubhaliswa Kwe-FDA Izovinjelwa Ukudayiswa.Ngokomthetho Wesimanjemanje We-Cosmetics Regulation Act ka-2022, osayinwe nguMongameli Biden ngomhla ka-29 Disemba 2022, zonke izimonyo ezithunyelwa e-United States kufanele zibe yi-FDA-registere...Funda kabanzi -
2023 I-API yesi-88 ECHINA
Ulwazi mayelana ne-JYMed ngo-2023 API CHINA 【esizeni】 Ngaphansi kobuholi bePhini Lomphathi Omkhulu u-Zhi Qin, i-Shenzhen JYMed Technology Co.,Ltd. (okuzobizwa kamuva nge-JYMed) ubambe iqhaza kulo mbukiso omkhulu. I-JYMed ibonise imikhiqizo enenzuzo i-Semaglutide, i-Liraglutide, i-Tirzepatide, i-O...Funda kabanzi -
Siyakwamukela ukuzohlangana nathi embukisweni we-API e-Qindao China JYMed stock: N4K32
Funda kabanzi -
I-JYMed ihlangane nawe kwa-PCHi
Ngemva kweminyaka emibili yokulindela, umbukiso we-2023 China International Cosmetics Personal and Home Care Raw Materials Exhibition (PCHi) wawukade ubanjelwe e-Guangzhou Canton Fair Complex ngo-February 15-17, 2023. I-PCHi umbukiso wezohwebo wamazwe ngamazwe ohlinzeka ngezimonyo zomhlaba wonke, ngokwe...Funda kabanzi -
I-Semeglutide API ye-Shenzhen JYMed yamukelwe yiqeqebana lokuqala le-NMPA yasekhaya futhi Ibhaliswe ku-US FDA (DMF No. 036009) enesimo esithi “A”.
NgoMeyi 2022, i-Shenzhen JYMed Technology Co., Ltd. (ngemuva kwalokhu ebizwa nge-JYMed peptide) yathumela isicelo sokubhaliswa kwe-semaglutide API ku-US Food and Drug Administration (FDA) (inombolo yokubhalisa ye-DMF: 036009), Iphumelele ukubuyekezwa kobuqotho, kanye nesimo samanje...Funda kabanzi
